Background: Patients presenting for cardiac surgery are often treated with angiotensin converting enzyme inhibitors Ž. Ž.ACEIs, either for heart failure or hypertension. Control of systemic vascular resistance SVR during surgery can be difficult in such patients. Angiotensin II has been available as an unlicensed vasoconstrictor, but there is concern about renal damage and its use. Aim: This study compared a standard vasoconstrictor with angiotensin II and examined the effect on renal function after cardiac surgery. Method: Twenty consecutive, consenting patients scheduled for cardiac surgery that had been taking ACEIs for at least 6 months, were randomly assigned to receive either phenylephrine or angiotensin II for the control of SVR duri...
OBJECTIVES: This study sought to examine whether the cardioprotective effects of angiotensin-convert...
Numerous strategies have been evaluated to prevent early CSA-AKI. Although correction of hemodynamic...
The peri‐operative use of angiotensin‐converting enzyme inhibitors or angiotensin‐2 receptor blocker...
Acute kidney injury is common after cardiac surgery. Vasoplegic hypotension may contribute to kidney...
2011 ACCF/AHA Guidelines for CABG: Uncertain about the safety of the preoperative administration of ...
Objectives: Several studies have shown angiotensin-converting enzyme (ACE) inhibitors to confer sign...
BACKGROUND: Despite several studies that evaluated the effects of renin-angiotensin system (RAS) inh...
BACKGROUND: There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angiote...
Based on these reports the omission of ACE inhibitors or angiotensin II receptor antagonists before ...
OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is a...
OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is a...
The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blo...
Background: Some studies have been performed to assess the effects of levosimendan on cardiac functi...
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors confer renal protection in different clin...
ObjectiveAcute kidney injury requiring renal replacement therapy in severe vasodilatory shock is ass...
OBJECTIVES: This study sought to examine whether the cardioprotective effects of angiotensin-convert...
Numerous strategies have been evaluated to prevent early CSA-AKI. Although correction of hemodynamic...
The peri‐operative use of angiotensin‐converting enzyme inhibitors or angiotensin‐2 receptor blocker...
Acute kidney injury is common after cardiac surgery. Vasoplegic hypotension may contribute to kidney...
2011 ACCF/AHA Guidelines for CABG: Uncertain about the safety of the preoperative administration of ...
Objectives: Several studies have shown angiotensin-converting enzyme (ACE) inhibitors to confer sign...
BACKGROUND: Despite several studies that evaluated the effects of renin-angiotensin system (RAS) inh...
BACKGROUND: There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angiote...
Based on these reports the omission of ACE inhibitors or angiotensin II receptor antagonists before ...
OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is a...
OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is a...
The effects of angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor blo...
Background: Some studies have been performed to assess the effects of levosimendan on cardiac functi...
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors confer renal protection in different clin...
ObjectiveAcute kidney injury requiring renal replacement therapy in severe vasodilatory shock is ass...
OBJECTIVES: This study sought to examine whether the cardioprotective effects of angiotensin-convert...
Numerous strategies have been evaluated to prevent early CSA-AKI. Although correction of hemodynamic...
The peri‐operative use of angiotensin‐converting enzyme inhibitors or angiotensin‐2 receptor blocker...